Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Human and canine ventricular vasoactive intestinal polypeptide: decrease with heart failure.

D V Unverferth, T M O'Dorisio, M M Miller

    The Journal of Laboratory and Clinical Medicine
    |July 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Closing the Digitalis Divide: Back to the Basics of Randomized Controlled Trials.

    Cardiovascular drugs and therapy·2021
    Same author

    Images in cardiology: Anomalous origin of the right coronary artery from the left anterior descending artery.

    Heart (British Cardiac Society)·2005
    Same author

    Contained myocardial rupture: a variant linking complete and incomplete rupture.

    Heart (British Cardiac Society)·2005
    Same author

    Calculation of creatinine clearance based on unadjusted body weight leads to errors in renal and heart failure patients.

    Circulation·2004
    Same author

    Mode of death in heart failure: findings from the ATLAS trial.

    Heart (British Cardiac Society)·2002
    Same author

    Nuggets, pearls, and vignettes of master heart failure clinicians. Part 1--the medical history.

    Congestive heart failure (Greenwich, Conn.)·2002
    Same journal

    Studies on streptomycin; assay in body fluids.

    The Journal of laboratory and clinical medicine·2010
    Same journal

    Gastrocolic fistula; an experimental study.

    The Journal of laboratory and clinical medicine·2010
    Same journal

    An isolated heart perfusion system adapted to the determination of nongaseous metabolities; with sample data upon the isolated monkey heart.

    The Journal of laboratory and clinical medicine·2010
    Same journal

    A new type of glass cage for metabolism studies.

    The Journal of laboratory and clinical medicine·2010
    Same journal

    A simple electrocardiograph contact electrode for use with the smaller laboratory animal.

    The Journal of laboratory and clinical medicine·2010
    Same journal

    A primary standard for the colorimetric determination of hemoglobin.

    The Journal of laboratory and clinical medicine·2010
    See all related articles

    Vasoactive intestinal polypeptide (VIP) levels significantly decrease in canine models of heart failure and in human hearts with advanced disease. This suggests VIP may play a role in cardiac function and failure.

    Area of Science:

    • Cardiology
    • Molecular Biology
    • Biochemistry

    Background:

    • Vasoactive intestinal polypeptide (VIP) is a known vasodilator with potential positive inotropic effects.
    • Alterations in VIP levels may be associated with cardiac dysfunction and heart failure.

    Purpose of the Study:

    • To investigate myocardial levels of VIP in experimental models of heart failure.
    • To compare VIP concentrations in human hearts with and without heart failure, considering underlying conditions like coronary artery disease.

    Main Methods:

    • Induction of cardiomyopathy in dogs using cobalt and doxorubicin to measure myocardial VIP levels via radioimmunoassay.
    • Assay of VIP content in left ventricular muscle and papillary muscles from human hearts of transplant recipients and valve replacement patients.

    Related Experiment Videos

  • Measurement of myocardial catecholamines and correlation with VIP levels.

    • Main Results:

    • Myocardial VIP levels decreased significantly in canine models of cobalt-induced and doxorubicin-induced heart failure.
    • Human hearts with advanced heart failure, particularly those with coronary artery disease, exhibited the lowest myocardial VIP concentrations.
    • VIP levels were significantly lower in failing hearts compared to non-failing hearts, with a weak positive correlation noted between VIP and norepinephrine.

    Conclusions:

    • Myocardial VIP levels are reduced in experimental and human heart failure.
    • VIP deficiency may contribute to the pathophysiology of heart failure, especially in the presence of coronary artery disease.
    • Further research is warranted to explore the therapeutic potential of VIP in managing heart failure.